Zhejiang Wolwo Bio-Pharmaceutical Adjusts Valuation Amid Strong Financial Performance

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation that reflects its evolving market position. The company's valuation score has been revised, indicating a shift towards a more favorable assessment of its financial metrics. Key indicators reveal a P/E ratio of 35, alongside a Price to Book Value of 5.01, suggesting a balanced valuation perspective. The company's EV to EBIT stands at 29.12, while the EV to EBITDA is recorded at 26.48, both of which provide insights into its operational efficiency. Additionally, the PEG ratio is noted at 1.41, which aligns with the company's growth trajectory. Zhejiang Wolwo has demonstrated robust financial performance, highlighted by a significant net profit growth of 60.38% in the quarter ending September 2025. The operating cash flow reached its peak at CNY 392.77 million, and the return on capital employed (ROCE) was recorded at 31.26%. With a dividend yield of 0.87% and a return on equity (ROE) of 14.15%, the company showcases a solid financial foundation. For more insights on the latest evaluation and financial trends, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.